AmerisourceBergen Approves Quarterly Dividend

  AmerisourceBergen Approves Quarterly Dividend

Business Wire

VALLEY FORGE, Pa. -- February 4, 2013

The Board of Directors of AmerisourceBergen Corporation (NYSE: ABC) today
declared a cash dividend of $0.21 per share on Common Stock, payable March 4,
2013, to stockholders of record at the close of business on February 15, 2013.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in the
pharmaceutical supply channel, the Company provides drug distribution and
related services designed to reduce costs and improve patient outcomes.
AmerisourceBergen's service solutions range from niche premium logistics and
pharmaceutical packaging to reimbursement and pharmaceutical consulting
services. With over $80 billion in annualized revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs approximately 14,500 people.
AmerisourceBergen is ranked #29 on the Fortune 500 list. For more information,
go to

Forward-Looking Statements

Certain of the statements contained in this press release are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. These statements are
based on management's current expectations and are subject to uncertainty and
change in circumstances. Among the factors that could cause actual results to
differ materially from those projected, anticipated or implied are the
following: changes in pharmaceutical market growth rates; the loss of one or
more key customer or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or insolvencies;
changes in pharmaceutical manufacturers' pricing and distribution policies or
practices; adverse resolution of any contract or other dispute with customers
or suppliers; federal and state government enforcement initiatives to detect
and prevent suspicious orders of controlled substances and the diversion of
controlled substances; qui tam litigation for alleged violations of fraud and
abuse laws and regulations and/or any other laws and regulations governing the
marketing, sale, purchase, and/or dispensing of pharmaceutical products or
services and any related litigation, including shareholder derivative
lawsuits; changes in federal and state legislation or regulatory action
affecting pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare; changes in regulatory or clinical medical
guidelines and/or labeling for the pharmaceutical products we distribute,
including certain anemia products; price inflation in branded pharmaceuticals
and price deflation in generics; greater or less than anticipated benefit from
launches of the generic versions of previously patented pharmaceutical
products; significant breakdown or interruption of our information technology
systems; our inability to realize the anticipated benefits of the
implementation of an enterprise resource planning (ERP) system; success of
integration, restructuring or systems initiatives; interest rate and foreign
currency exchange rate fluctuations; risks associated with international
business operations, including non-compliance with the U.S. Foreign Corrupt
Practices Act, anti-bribery laws and economic sanctions and import laws and
regulations; economic, business, competitive and/or regulatory developments
outside of the United States; changes and/or potential changes in Canadian
provincial legislation affecting pharmaceutical product pricing or service
fees or regulatory action by provincial authorities in Canada to lower
pharmaceutical product pricing and service fees; the impact of divestitures or
the acquisition of businesses that do not perform as we expect or that are
difficult for us to integrate or control; our inability to successfully
complete any other transaction that we may wish to pursue from time to time;
changes in tax laws or legislative initiatives that could adversely affect our
tax positions and/or our tax liabilities or adverse resolution of challenges
to our tax positions; increased costs of maintaining, or reductions in our
ability to maintain, adequate liquidity and financing sources; volatility and
deterioration of the capital and credit markets; and other economic, business,
competitive, legal, tax, regulatory and/or operational factors affecting our
business generally. Certain additional factors that management believes could
cause actual outcomes and results to differ materially from those described in
forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the
Company's Annual Report on Form 10-K for the fiscal year ended September 30,
2012 and elsewhere in that report and (ii) in other reports filed by the
Company pursuant to the Securities Exchange Act of 1934.


AmerisourceBergen Corporation
Barbara Brungess, 610-727-7199
Press spacebar to pause and continue. Press esc to stop.